| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenue | $233.1M+39.0% | $167.7M+155.8% | $65.6M+360.8% | $14.2M+2251.2% | $605K |
| Total cost of revenue | $164.9M+36.1% | $121.1M+160.4% | $46.5M+314.7% | $11.2M+15479.2% | $72K |
| Gross profit | $362.8M+38.4% | $262.1M+70.1% | $154.1M+136.1% | $65.3M+208.5% | $21.2M |
| Research, development and clinical trials | $69.1M+23.4% | $56.0M+55.2% | $36.1M+34.5% | $26.8M+20.2% | $22.3M |
| Acquired in-process research and development expenses | $27.2M | — | — | — | — |
| Selling, general and administrative | $185.2M+9.8% | $168.6M+41.0% | $119.6M+71.0% | $69.9M+82.6% | $38.3M |
| Total operating expenses | $254.2M+13.2% | $224.6M+22.8% | $182.8M+89.0% | $96.7M+59.6% | $60.6M |
| Income (loss) from operations | $108.6M+189.6% | $37.5M+230.5% | -$28.7M+8.6% | -$31.4M+20.3% | -$39.4M |
| Interest expense | -$13.8M+4.4% | -$14.4M-33.5% | -$10.8M-189.6% | -$3.7M+3.8% | -$3.9M |
| Interest income and other income (expense), net | $12.7M+0.2% | $12.7M-1.2% | $12.8M+1382.1% | -$1.0M | — |
| Total other income (expense), net | -$1.1M+38.2% | -$1.7M-183.5% | $2.1M+143.5% | -$4.7M+0.5% | -$4.8M |
| Income (loss) before income taxes | $107.5M+200.5% | $35.8M+234.2% | -$26.7M+26.3% | -$36.2M+18.1% | -$44.2M |
| (Provision) benefit for income taxes | $82.8M+26292.7% | -$316K-119.2% | $1.6M+2589.4% | -$66K-83.3% | -$36K |
| Net income (loss) | $190.3M+436.6% | $35.5M+241.7% | -$25.0M+30.9% | -$36.2M+18.1% | -$44.2M |
| Net income (loss) per share, basic | $5600.00+423.4% | $1070.00+239.0% | -$770.00+37.4% | -$1230.00+23.1% | -$1600.00 |
| Net income (loss) per share, diluted | $4870.00+382.2% | $1010.00+231.2% | -$770.00+37.4% | -$1230.00+23.1% | -$1600.00 |
| Weighted average common shares outstanding, basic | 33.99B+2.3% | 33.23B+2.2% | 32.52B+10.0% | 29.56B+7.0% | 27.62B |
| Weighted average common shares outstanding, diluted | 40.54B+15.1% | 35.22B+8.3% | 32.52B+10.0% | 29.56B+7.0% | 27.62B |
| Net product revenue [Member] | |||||
| Service Revenue [Member] | |||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.